Reports with headlines such as “psychedelic therapy is no more effective than antidepressants” understandably attract a great deal of attention. They touch upon an important question: if both approaches show, on average, approximately the same amount of improvement in research, does that mean they are interchangeable? In practice, that conclusion is often too definitive. The way studies are compared, what exactly falls under “therapy,” and which outcomes are measured make a fair comparison complex.
In this article, we explain why psychedelic therapy and antidepressants are difficult to compare one-to-one, what can and cannot be deduced from such comparisons, and the associated uncertainties. We make no medical claims and do not provide individual advice. We primarily discuss methodology, context, and harm reduction.
What often goes wrong with “comparative” headlines
Many news articles and summaries rely on indirect comparisons: researchers juxtapose results from different studies and attempt to deduce how two treatments compare to each other. This is different from a direct, randomized “head-to-head” study in which the same population is compared using the same measurement points and the same outcome measures.
Indirect comparisons can be useful, but they have limitations. Studies differ, for example, in selection criteria, severity of symptoms, duration of symptoms, comorbidity, previous treatments, and how strictly additional support is monitored. If one study primarily includes people who have already tried many things and the other study includes people who are just starting treatment, then “equal effect on average” says little about what is actually the same.
Publication bias also plays a role: positive results are published more often and more quickly. Moreover, small studies with a striking effect may contain more statistical noise. This makes it especially important to translate headlines back to the underlying data and methods.
Psychedelic therapy is not a “pill for depression”
A crucial point in this debate is that psychedelic therapy usually does not revolve solely around the substance. It is a combination of preparatory conversations, the acute experience (the session), guidance during the session, and integration afterwards. The “active components” are therefore interwoven: set (mindset, expectations), setting (environment, safety), and the therapeutic relationship and approach.
Antidepressants are often studied as daily medication, with periodic evaluations, sometimes in combination with counseling. In research, the context can vary: some studies offer extensive guidance, others minimal. If you then compare the outcomes of “psychedelic therapy in an intensively supervised protocol” with “open-label antidepressants in a less intensive protocol,” you are not only comparing two biochemical interventions, but also two completely different forms of care.
That does not mean that one of the two is by definition “better.” It does mean, however, that the concept of “effectiveness” has multiple layers here: the effect of the material, the effect of guidance, the effect of expectation, and the effect of attention and structure.
Why open-label antidepressants are a unique basis for comparison
Some comparisons involve open-label antidepressants. Open-label means that participants know what they are receiving. This can influence expectations and reporting, both positively and negatively. Incidentally, the same often applies to psychedelic studies, because blinding is difficult: many participants quickly notice from the effects whether they have received a placebo or a low dose.
When both sides suffer from “imperfect blinding,” this can distort the comparison. Expectation effects can strengthen or weaken outcomes. Furthermore, antidepressants are often adjusted in terms of type and dosage in daily practice, whereas a study protocol sometimes restricts this. Conversely, psychedelic protocols in research are often strictly standardized, whereas practice outside of research varies.
The outcome “equally effective” can therefore mean several things: perhaps they really do work about equally well on average, or perhaps we are measuring partly context, expectation, and selection effects.
Which outcomes do we actually measure, and when?
A second major source of unfairness in comparisons is the choice of outcome measures and measurement points. Many studies use symptom scales for depression at specific time points, for example after 4, 6, or 12 weeks. Antidepressants are often assessed over a period of weeks to months, whereas psychedelic studies sometimes report strong short-term changes after one or a few sessions, with follow-ups varying by study.
If the measurement points are not the same, it becomes difficult to make statements about sustainability. An intervention can have a quick effect but decline just as quickly, or conversely build up slowly but last longer. Without the same follow-up duration and a comparable context, “equal effectiveness” is, in fact, a snapshot.
Furthermore, it is not just about symptoms. Some people place great value on functioning, quality of life, purpose, sleep, relationships, or reducing avoidance. Not every study measures these domains to the same extent. This increases the risk that a simple score will come to dominate the entire picture.
What works for whom: hide averages subgroups
Even if two approaches score similarly on average, this says little about individual differences. Averages can mask subgroups: some participants respond strongly, while others respond hardly at all. It may be that antidepressants are a better fit for certain profiles, and that intensive, experiential therapy is a better match for others. Exactly which factors these are is still the subject of research.
Previous treatment history can also make a significant difference. “Treatment-resistant” depression is not the same as a first depressive episode. A history of trauma, dissociation, anxiety symptoms, substance use, and social stressors can likewise influence the response. If studies include different populations, the average automatically shifts accordingly.
Therefore, it is wise to read conclusions as: “in this collection of studies, with these groups and these measurement methods, researchers found no clear difference in average symptom reduction.” That is different from: “it doesn’t matter what you choose.”
Safety and risks: not the same profile, not the same questions
A fair comparison concerns not only effect, but also safety, risks, and practical feasibility. Antidepressants have known side effects and interactions and are typically monitored by a prescriber. Psychedelic sessions bring other points of attention: acute psychological strain during the experience, possible dysregulation afterwards, and the significant role of screening, preparation, guidance, and integration.
The framework is also important. Currently, MDMA sessions can only be discussed and supervised within scientific research or in clinical practice via harm reduction. In practice, this means an emphasis on risk mitigation, clear boundaries, screening where possible, and not claiming medical treatment. This framework is not the same as regular mental healthcare, nor is it the same as “doing it yourself without supervision.”.
Moreover, regarding harm reduction, uncertainties are sometimes greater: the quality and dosage of medications are not guaranteed outside of research, and an individual's physical and psychological risk factors require careful consideration. This is precisely why generalizing comparisons in the media quickly fall short.
What you *can* take away from these kinds of comparisons
Comparisons can help temper hype. They serve as a reminder that psychedelic therapy is not automatically “superior,” and that the burden of proof varies by indication and protocol. At the same time, they also show that the research field is maturing: there is more attention to control groups, comparison with existing care, and better definition of outcomes.
If you want to read the underlying article or summary that this discussion often refers to, see the source: Psychedelic therapy is no more effective than open-label antidepressants for depression, according to a comparison by researchers.. Please note: the type of comparison (direct or indirect), the populations, and the follow-up duration determine what you can conclude from it.
Conclusion
Psychedelic therapy and antidepressants are difficult to compare fairly because they often involve indirect comparisons between different studies, with different groups, contexts, and measurement points. Additionally, psychedelic therapy is usually a combination of experience, setting, and guidance, whereas antidepressants are generally studied as daily medication. Therefore, “equally effective on average” does not mean that they work the same way, for the same people, or have the same long-term impact.
Anyone interested in exploring an MDMA session in a harm-reduction context can read more and sign up via sign up for MDMA session. This is not medical advice and no guarantee of outcome, but a practical first step to carefully explore information and possibilities.
English 
Dutch 
German 
French